Gupta, V.K., Giri, R. and Agrawal, S. 2021. Dipeptidyl peptidase-4 inhibitor (teneligliptin) significantly reduces liver fat content and delays progression of non-alcoholic steatohepatitis in type 2 diabetes mellitus patients. International Journal of Advances in Medicine. 8, 12 (Nov. 2021), 1817–1820. DOI:https://doi.org/10.18203/2349-3933.ijam20214516.